INDIANAPOLIS — There were several developments in the coronavirus pandemic that you may have missed overnight.
Here’s a look:
Emergency use. Pfizer and BioNTech say they’ve won permission Wednesday for emergency use of their COVID-19 vaccine in Britain, the world’s first coronavirus shot that’s backed by rigorous science — and a major step toward eventually ending the pandemic.
The move makes Britain one of the first countries to begin vaccinating its population as it tries to curb Europe’s deadliest COVID-19 outbreak.
Pfizer said it would immediately begin shipping limited supplies to the U.K. — and has been gearing up for even wider distribution if given a similar nod by the U.S. Food and Drug Administration, a decision expected as early as next week.
But doses everywhere are scarce, and initial supplies will be rationed until more is manufactured in the first several months of next year.
Pfizer CEO Albert Bourla called the U.K. decision “a historic moment.”
“We are focusing on moving with the same level of urgency to safely supply a high-quality vaccine around the world,” Bourla said in a statement.
While the U.K. has ordered enough Pfizer vaccine for 20 million people, it’s not clear how many will arrive by year’s end and adding to the distribution challenges is that it must be stored at ultra-cold temperatures.
Two doses three weeks apart are required for protection. First in line, the U.K. government says, are frontline health care workers and nursing home residents, followed by older adults.
British regulators also are considering another shot made by AstraZeneca and Oxford University. But Prime Minister Boris Johnson has warned “we must first navigate a hard winter” of restrictions to try to curb the virus until there’s enough vaccine to go around.
Vaccine vote. Health care workers and nursing home residents should be at the front of the line when the first coronavirus vaccine shots become available in the U.S., an influential government advisory panel said Tuesday.
The panel voted 13-1 to recommend those groups get priority in the first days of any coming vaccination program, when doses are expected to be very limited. The two groups encompass about 24 million people out of a U.S. population of about 330 million.
Later this month, the Food and Drug Administration will consider authorizing emergency use of two vaccines made by Pfizer and Moderna. Current estimates project that no more than 20 million doses of each vaccine will be available by the end of 2020. And each product requires two doses. As a result, the shots will be rationed in the early stages.
The Advisory Committee on Immunization Practices will meet again at some point to decide who should be next in line. Among the possibilities: teachers, police, firefighters and workers in other essential fields such as food production and transportation; the elderly; and people with underlying medical conditions.
Tuesday’s action merely designated who should get shots first if a safe and effective vaccine becomes available. The panel did not endorse any particular vaccine. Panel members are waiting to hear FDA’s evaluation and to see more safety and efficacy data before endorsing any particular product.
Experts say the vaccine will probably not become widely available in the U.S. until the spring.
The panel of outside scientific experts, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention, who almost always approves them. It normally has 15 voting members, but one seat is vacant.
The recommendations are not binding, but for decades they have been widely heeded by doctors, and they have determined the scope and funding of U.S. vaccination programs.
Shorter quarantine. The Centers for Disease Control and Prevention is set to shorten the recommended length of quarantine after exposure to someone who is positive for COVID-19, as the virus rages across the nation.
According to a senior administration official, the new guidelines, which are set to be released as soon as Tuesday evening, will allow people who have come in contact to someone infected with the virus to resume normal activity after 10 days, or 7 days if they receive a negative test result.
That’s down from the 14-day period recommended since the onset of the pandemic.
The official, who spoke on the condition of anonymity to preview the announcement, said the policy change has been discussed for some time, as scientists have studied the incubation period for the virus. The policy would hasten the return to normal activities by those deemed to be “close contacts” of those infected with the virus, which has infected more than 13.5 million Americans and killed at least 270,000.COVID-19 hospitalizations in US soar to new daily record
While the CDC had said the incubation period for the virus was thought to extend to 14 days, most individuals became infectious and developed symptoms between 4 and 5 days after exposure.
It’s not the first time that the CDC has adjusted its guidance for the novel coronavirus as it adjusted to new research. In July the agency shortened, from 14 days to 10, its advice on how long a person should stay in isolation after they first experience COVID symptoms — provided they’re no longer sick.If you traveled for Thanksgiving, ‘assume you were exposed,’ Birx says
The new guidance was presented Tuesday at a White House coronavirus task force meeting for final approval.
Stimulus update. A bipartisan group of lawmakers is putting pressure on congressional leaders to accept a split-the-difference solution to the protracted impasse over COVID-19 relief in a last-gasp effort to ship overdue help to a hurting nation before Congress adjourns for the holidays.
The group includes Senate centrists such as Joe Manchin, D-W.Va., and Susan Collins, R-Maine, who hope to exert greater influence in a closely divided Congress during the incoming Biden administration.
In Wilmington, Delaware, President-elect Joe Biden called on lawmakers to approve a down payment on COVID relief, though he cautioned that “any package passed in lame-duck session is — at best — just a start.”
What’s missing? The stimulus check that was included in the first COVID-19 relief bill.
The proposal hit the scales at $908 billion, including $228 billion to extend and upgrade “paycheck protection” subsidies for businesses for a second round of relief to hard-hit businesses like restaurants. It would revive a special jobless benefit, but at a reduced level of $300 per week rather than the $600 benefit enacted in March. State and local governments would receive $160 billion, and there is also money for vaccines.
Earlier, larger versions of the proposal — a framework with only limited detail — were rejected by top leaders such as House Speaker Nancy Pelosi, D-Calif., and Senate Majority Leader Mitch McConnell, R-Ky. But pressure is building as lawmakers face the prospect of heading home for Christmas and New Year’s without delivering aid to people in need.
It comes after a split-decision election delivered the White House to Democrats and gave Republicans down-ballot success. At less than $1 trillion, the plan is less costly than a proposal meshed together by McConnell this summer. He later abandoned that effort for a considerably less costly measure that failed to advance in two attempts this fall.